Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Study of Prostate Cancer Screening - 23-Year Follow-up.

The New England journal of medicine·2026
Same author

Sad But True: Inconsistent Care for Invasive Bladder Cancer.

JCO oncology practice·2026
Same author

Circulating Tumor Cells and Clinical Outcomes in Men with Metastatic Castration-sensitive Prostate Cancer Treated with Enzalutamide and Docetaxel: An Analysis of the ENZADA Trial.

European urology open science·2025
Same author

The Financial Toxicity Tumor Board: 5-Year Update on Practice and a Guide to Implementation.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same author

Abstract Thinking and Statins With Immune Checkpoint Inhibitors: Enough to Change Clinical Practice?

JCO oncology practice·2025
Same author

Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial.

Clinical genitourinary cancer·2025
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
Same journal

Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.

The oncologist·2026
Same journal

Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors.

The oncologist·2026
Same journal

Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study.

The oncologist·2026
Same journal

Patient, Care Partner, and Oncologist Perspectives on Clinically Important Survival Thresholds After Considering Time Toxicity in Advanced Cancer.

The oncologist·2026
Same journal

Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer.

The oncologist·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
09:24

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

Published on: September 13, 2018

Invasive bladder cancer: ignoring the data

Derek Raghavan

    The Oncologist
    |August 30, 2013
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Culture of Bladder Cancer Organoids as Precision Medicine Tools
    08:39

    Culture of Bladder Cancer Organoids as Precision Medicine Tools

    Published on: December 28, 2021

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
    11:02

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

    Published on: October 30, 2013

    Related Experiment Videos

    Last Updated: May 8, 2026

    3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
    09:24

    3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

    Published on: September 13, 2018

    Culture of Bladder Cancer Organoids as Precision Medicine Tools
    08:39

    Culture of Bladder Cancer Organoids as Precision Medicine Tools

    Published on: December 28, 2021

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
    11:02

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

    Published on: October 30, 2013